Maxence Cornut

Maxence CORNUT has a background in research and project management in the field of biotechnology and pharmaceuticals. Maxence worked as a Client Project Manager at TransCure bioServices starting in October 2022. Prior to this, they were an Assisting Product Manager at Gedeon Richter France from September 2021 to September 2022. In 2021, they also had a Marketing Project role at ESTBB - Ecole Supérieure de Biologie - Biochimie - Biotechnologies from October to November.

Maxence also has extensive experience in research, particularly in the area of inflammasome, bacterial infections, and autoinflammation. Maxence completed their PhD at CIRI Centre international de Recherche en Infectiologie from October 2017 to December 2020, focusing on the transcriptional regulations of inflammasome-related genes. During their PhD, Maxence acquired expertise in various techniques including immunology, bacteriology, virology, and molecular biology. Maxence also obtained a French university diploma in the design of animal testing experiments.

Before their PhD, Maxence worked as a Project Manager in research at Inserm. Maxence worked on Lipids (eicosanoids) - AIM2 Inflammasome interactions during Francisella tularensis infection in the first half of 2017. Maxence also had a brief role as a Project Manager at Inserm in 2016.

Maxence CORNUT completed their education in a chronological order as follows:

From 2015 to 2017, Maxence CORNUT pursued a Master's degree in Cellular Biology and Genetics at Université Claude Bernard Lyon 1.

In 2017, they began their PhD program in Infectiology at Université Claude Bernard Lyon 1, which lasted until 2020.

In 2019, Maxence CORNUT also obtained a Regulatory formation related to animal testing procedures (Level 1) at Université Claude Bernard Lyon 1.

In 2021, they enrolled at l'ESTBB to study Management of health and biotechnology industries, which they completed in 2022.

Additionally, in the same year 2021, Maxence CORNUT pursued a program in Management of health industries and biotechs, with a focus on IRPOB, at Université catholique de Lyon.